|
BioTrinity 2008 - Oxford, April 15-16, 2008
South-East's Largest Biopartnering Conference and
Showcase
OBN invites you to participate in BioTrinity, the
South-East England’s equivalent of the ERBI BioExchange. With
just a few weeks to go before BioTrinity 2008 can you
afford to be missing from the list of nearly 200 companies
already confirmed for April 15-16 in Oxford?
Partnering is live! Register online
now
...........................................................................................
Oxford BioMedica develops strategic
development plan with the commercialisation of TroVax
BioTrinity 2008 - Oxford announces a highly
relevant new addition to its programme. Oxfordshire Bioscience
Networks' leading partnering and networking event confirmed that
Peter Nolan, SVP Commercial Development at Oxford BioMedica, will
discuss the company's deal with sanofi-aventis to develop and
commercialise TroVax® for the treatment and prevention of cancers.
This follows the announcement that the TRIST trial successfully
completed patient enrolment.
TroVax® is Oxford BioMedica's lead cancer
immunotherapy. Based on the broad distribution of the 5T4 tumour
antigen, TroVax® has potential application in a wide range of solid
tumours, including renal, colorectal, lung, breast and prostate
cancer. Earlier this month Oxford BioMedica announced that it has
successfully completed patient enrolment in the Phase III TRIST
study.
690 patients have been randomised to-date and a
sufficient number of additional patients are being screened for
inclusion such that the total enrolment is expected to slightly
exceed the target of 700 patients. Over 100 sites in the USA,
European Union and Eastern Europe have recruited patients into the
trial. The trial started in November 2006; recruitment has been
completed on schedule and final results from the study are
anticipated in the first half of 2009.
Peter Nolan commented "I am delighted to be
speaking at BioTrinity 2008, which is an opportune platform on which
we can discuss the recent milestones achieved in the development of
TroVax, our lead cancer immunotherapy."
BioTrinity 2008 is taking place on April 15-16,
2008 in Oxford, UK and provides the opportunity to view the latest
presentations from the most promising companies within the UK's most
successful biotech super-cluster in Oxford and the South East of
England.
...........................................................................................
Register now and start partnering: www.biotrinity.com
............................................................................................
Contact details:
Jon Rees, Network Director, OBN
Suite L, Park House
11 Milton Park, Abingdon
Oxfordshire OX14 4RA
Tel. +44 (0)
1865 594640
Fax. +44 (0) 1235 835843
jon.rees@oxfordshirebioscience.net
Register online now at www.biotrinity.com
............................................................................................
BioTrinity sponsors
  
  
  
  
 
............................................................................................
BioTrinity partners
  
  
............................................................................................
BioTrinity is organised by OBN
| 
267
delegates already confirmed
)